(secondQuint)A Study to Evaluate the Efficacy and Safety of Radion-Pdt in Patients With Oral Precancerous Lesion.

 This is a single-center, single-arm, open-label study to evaluate the efficacy and safety of topical Radion cent -pdt for treatment of patients with oral verrucous hyperplasia (OVH) or oral erythroleukoplakia (OEL).

 Total duration of the study will be up to 40 weeks (from screening throughout study until completion) as follows: - Screening (within 2 weeks before dosing) - Treatment period (up to 14 weeks) - Safety follow-up period (within 2 weeks after final treatment) - Follow-up period (final treatment plus 4 weeks, 8 weeks, 16 weeks and 24 weeks respectively) All enrolled patients will receive up to 8 treatments (once every two weeks) during a maximum of 14-week study treatment period.

 The treated lesion will be clinically evaluated and documented (clinical photograph) at each treatment visit.

.

 A Study to Evaluate the Efficacy and Safety of Radion-Pdt in Patients With Oral Precancerous Lesion@highlight

A Prospective, Single-Arm, Open-Label, Phase II Study to Evaluate the Efficacy and Safety of Photodynamic Therapy Using Radion cent -pdt in Patients with Oral Precancerous Lesion (Oral Verrucous Hyperplasia or Oral Erythroleukoplakia).

